Clinical Trials Logo
  1. Home
  2. Naloxone
  3. NCT04677387

Nalox-Comm: Naloxone Communication Training for Pharmacists — Nalox-Comm  

Naloxone Clinical Trial

Official title:
Addressing the Opioid Epidemic Through Community Pharmacy Engagement: Randomized Controlled Trial (Aim 2)

Clinical Trial Summary

This is a pilot Randomized Controlled Trial (RCT) in which 120 pharmacists will be randomized to an experimental or control group and data on naloxone dispensing and secondary outcomes will be collected over the course of the RCT.

Clinical Trial Description

This is a prospective pilot RCT that will evaluate the impact of naloxone communication training (Nalox-Comm) on 120 pharmacists' naloxone dispensing behaviors (primary outcome). Data will be collected at baseline, immediately after training is completed, and at 3-month follow up. Data sources include pharmacy records (for naloxone dispensing), simulated patient observations (to rate quality of communication), and survey data (for self-reports of knowledge and self-efficacy). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04677387
Study type Interventional
Source University of North Carolina, Chapel Hill
Contact
Status Completed
Phase N/A
Start date July 1, 2021
Completion date July 31, 2023
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03280966 - Effects of Intranasal Naloxone on Gambling Urges in Gambling Disorder Phase 2
Completed NCT00723697 - Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)
Completed NCT01935206 - Effect of High Dose Naloxone on Secondary Hyperalgesia Phase 1
Not yet recruiting NCT06429436 - Vending Machine Naloxone Distribution for Your Community (VENDY) Phase 4
Completed NCT04303000 - Increasing Naloxone Access for Persons Who Use Opioids Phase 4
Not yet recruiting NCT06251609 - Naloxone for Opioid Associated Out of Hospital Cardiac Arrest Phase 2
Enrolling by invitation NCT03430180 - Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder Phase 2
Completed NCT03223896 - Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray Phase 2
Completed NCT04025671 - A Usability Assessment of Naloxone Administration by Untrained Community Members N/A